KR102182563B1 - 비당뇨성 포유동물에서 암컷 불임 치료를 위한 텅스텐 (vi) 염의 용도 - Google Patents

비당뇨성 포유동물에서 암컷 불임 치료를 위한 텅스텐 (vi) 염의 용도 Download PDF

Info

Publication number
KR102182563B1
KR102182563B1 KR1020157022529A KR20157022529A KR102182563B1 KR 102182563 B1 KR102182563 B1 KR 102182563B1 KR 1020157022529 A KR1020157022529 A KR 1020157022529A KR 20157022529 A KR20157022529 A KR 20157022529A KR 102182563 B1 KR102182563 B1 KR 102182563B1
Authority
KR
South Korea
Prior art keywords
tungsten
salt
treatment
female
drug according
Prior art date
Application number
KR1020157022529A
Other languages
English (en)
Korean (ko)
Other versions
KR20150130992A (ko
Inventor
알마잔 이그나시오 카날스
부지에 아그네스 아르바트
Original Assignee
옥소라이프, 에스.엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49999950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102182563(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 옥소라이프, 에스.엘. filed Critical 옥소라이프, 에스.엘.
Publication of KR20150130992A publication Critical patent/KR20150130992A/ko
Application granted granted Critical
Publication of KR102182563B1 publication Critical patent/KR102182563B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physiology (AREA)
KR1020157022529A 2013-01-22 2014-01-21 비당뇨성 포유동물에서 암컷 불임 치료를 위한 텅스텐 (vi) 염의 용도 KR102182563B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ESP201330071 2013-01-22
ES201330071A ES2478790B1 (es) 2013-01-22 2013-01-22 Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
PCT/EP2014/051141 WO2014114644A1 (en) 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Publications (2)

Publication Number Publication Date
KR20150130992A KR20150130992A (ko) 2015-11-24
KR102182563B1 true KR102182563B1 (ko) 2020-11-25

Family

ID=49999950

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157022529A KR102182563B1 (ko) 2013-01-22 2014-01-21 비당뇨성 포유동물에서 암컷 불임 치료를 위한 텅스텐 (vi) 염의 용도

Country Status (27)

Country Link
US (1) US9675638B2 (ru)
EP (1) EP2948156B1 (ru)
JP (1) JP6045721B2 (ru)
KR (1) KR102182563B1 (ru)
CN (1) CN105188721B (ru)
AU (1) AU2014209987B2 (ru)
BR (1) BR112015017483A2 (ru)
CA (1) CA2898953C (ru)
CL (1) CL2015002047A1 (ru)
CY (1) CY1118287T1 (ru)
DK (1) DK2948156T3 (ru)
ES (2) ES2478790B1 (ru)
HK (1) HK1217442A1 (ru)
HR (1) HRP20161611T1 (ru)
HU (1) HUE031910T2 (ru)
IL (1) IL240062B (ru)
LT (1) LT2948156T (ru)
MX (1) MX356851B (ru)
NZ (1) NZ710583A (ru)
PL (1) PL2948156T3 (ru)
PT (1) PT2948156T (ru)
RS (1) RS55418B1 (ru)
RU (1) RU2635507C2 (ru)
SG (1) SG11201505701WA (ru)
SI (1) SI2948156T1 (ru)
SM (1) SMT201700018B (ru)
WO (1) WO2014114644A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639588B1 (es) * 2014-05-21 2018-09-06 Oxolife, S.L. Uso de una sal de tungsteno (VI) para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
HUE061726T2 (hu) * 2014-07-21 2023-08-28 Oxolife Sl Wolfrám (VI) sók termékenység és reprodukció stimulálására és elõsegített reprodukciós technika hatékonyságának fokozására
EP4368577A1 (en) * 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122209B2 (en) * 2001-05-16 2006-10-17 Quimica Farmaceutica Bayer S.A. Oral compositions for the treatment of non-diabetic obese mammals, including humans

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642B1 (es) * 1995-07-26 1998-08-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
RU2141361C1 (ru) * 1998-03-12 1999-11-20 Пермская государственная медицинская академия Способ лечения ановуляторного бесплодия при ожирении
AU2002368261A1 (en) * 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
RU2270684C1 (ru) * 2005-01-20 2006-02-27 Анатолий Григорьевич Гриценко Лекарственный препарат "витасорб"
JP2009502891A (ja) * 2005-07-29 2009-01-29 ユニベルシダード デ バルセロナ 神経変性疾患、特にアルツハイマー病及び統合失調症の治療のためのタングステン酸塩（ｖｉ）を含有してなる製薬的組成物
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7122209B2 (en) * 2001-05-16 2006-10-17 Quimica Farmaceutica Bayer S.A. Oral compositions for the treatment of non-diabetic obese mammals, including humans

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Burks et al, Nature. 2000 Sep 21;407(6802):377-382*

Also Published As

Publication number Publication date
MX356851B (es) 2018-06-18
ES2478790A1 (es) 2014-07-22
DK2948156T3 (da) 2017-01-02
AU2014209987A1 (en) 2016-01-21
AU2014209987B2 (en) 2016-09-01
CL2015002047A1 (es) 2016-01-04
CY1118287T1 (el) 2017-06-28
SMT201700018B (it) 2017-03-08
HK1217442A1 (zh) 2017-01-13
KR20150130992A (ko) 2015-11-24
PL2948156T3 (pl) 2017-07-31
MX2015009364A (es) 2016-03-08
RU2635507C2 (ru) 2017-11-13
ES2611776T3 (es) 2017-05-10
CN105188721A (zh) 2015-12-23
EP2948156B1 (en) 2016-10-26
RU2015135578A (ru) 2017-03-02
SG11201505701WA (en) 2015-08-28
JP2016505057A (ja) 2016-02-18
IL240062B (en) 2018-11-29
BR112015017483A2 (pt) 2017-07-11
PT2948156T (pt) 2016-11-30
CA2898953C (en) 2018-01-02
JP6045721B2 (ja) 2016-12-14
RS55418B1 (sr) 2017-04-28
US20150359820A1 (en) 2015-12-17
CN105188721B (zh) 2017-10-31
IL240062A0 (en) 2015-09-24
HRP20161611T1 (hr) 2017-01-27
NZ710583A (en) 2016-06-24
US9675638B2 (en) 2017-06-13
SI2948156T1 (sl) 2017-02-28
HUE031910T2 (en) 2017-08-28
CA2898953A1 (en) 2014-07-31
LT2948156T (lt) 2016-12-27
ES2478790B1 (es) 2015-05-06
EP2948156A1 (en) 2015-12-02
WO2014114644A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
Eriksson et al. Increased incidence of congenital malformations in the offspring of diabetic rats and their prevention by maternal insulin therapy
Cushing The hypophysis cerebri clinical aspects of hyperpituitarism and of hypopituitarism
PITKIN et al. Fetal effects of maternal streptozotocin-diabetes
O'toole et al. Vitamin A deficiency and reproduction in rhesus monkeys
KR102182563B1 (ko) 비당뇨성 포유동물에서 암컷 불임 치료를 위한 텅스텐 (vi) 염의 용도
Renz et al. new macrofilaricidal drug screen, Onchocerca ochengi
CN107412216B (zh) α-酮戊二酸在改善高脂饮食导致的动物繁殖功能损伤方面的应用
Kotz et al. Treatment of Recurrent and Threatened Abortion Report of Two Hundred and Twenty-six Cases
Nasser et al. Effect of different oestrus synchronizations protocols on the reproductive efficiency of Dammar ewes in Yemen during winter
Dávila et al. Reproduction in Small Ruminants (Goats)
Aguillar-Gomes et al. Toxic effects of glibenclamide in fetuses of normoglycemic rats: an alternative therapy for gestational diabetes mellitus
EP2133082B1 (en) THE USE OF GINSENOSIDE Rg1, ITS METABOLITES GINSENOSIDE Rh1 AND/OR PpT
Murphy Studies on precocious maturity in artificially reared 1+ Atlantic salmon parr Salmo salar L.
Yildiz et al. Changes in the uterus and vagina of rats with experimentally induced diabetes and the effect of lycopene on the changes.
CN112807296B (zh) 琥珀酸在诊断或治疗自然流产中的应用
Ujah et al. Insulin and Zinc Co-Administration Ameliorate Diabetes Mellitus-Induced Reproductive Dysfunction in Male Rats
CN115944644B (zh) 一种具有改善卵巢功能减退功效的组合物及其应用
Marius Deac et al. Including Natural and Synthetic PGF2α in a 11-day FGA-Based Estrus Synchronization Protocol in Sheep: an Efficacy Comparison of Dinoprost and Cloprostenol.
Deac et al. Including Natural and Synthetic PGF2α in a 11-day FGA-Based Estrus Synchronization Protocol in Sheep: an Efficacy Comparison of Dinoprost and Cloprostenol
Jamil et al. Effects of gonadotropin releasing hormone (GnRH) administration on serum hormonal and mineral profiles and pregnancy rate during breeding and early non-breeding season in female dromedary camel.
Shpiner Further studies on the alleged interrelationship of the pancreas and the thyroid
Watts et al. Calcium cloprostenol administered at a continuous low dosage induces luteolysis and abortion in bitches
CN117695324A (zh) 杜仲雄花花粉和/或杜仲雄花的新用途以及包含其的组合物
Gruffydd-Jones The reproductive system
Okouyi M’foumou W’otari et al. USE OF PROGESTOGENS TO THE HORMONAL MANAGEMENT OF REPRODUCTION IN THE N’DAMA COW IN GABON.

Legal Events

Date Code Title Description
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant